Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2393MR)

This product GTTS-WQ2393MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2393MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1219MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ1954MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ219MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ9730MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ10399MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ3547MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ10777MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ7691MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW